Similarly, HER2 heterogeneity was associated with higher rate of anti-HER2 therapy compared with HER2-negative patients (72.7% vs. 0.0%, p < 0.001), and once again, no significant difference was observed among patients with at least one HER2+ tumor focus (72.7% vs. 77.5%, p = 0.711, Figure 2E). This evidence concerns the gene ERBB2 and neoplasm.